Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

DoD Seeks New Drug for Alphaviruses

by Stephanie Lizotte
March 20, 2012

The Department of Defense (DoD) is soliciting proposals for small molecule drug candidates for treatment of or prevention against alphavirus-induced encephalitis.

Venezuelan Equine Encephalitis (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Western Equine Encephalitis Virus (WEEV) are zoonotic mosquito-borne viruses that infect both equines and humans, and potentially cause significant morbidity and mortality. Since these viruses pose a serious threat to human health and are considered potential biological weapons, an urgent need exists under the Joint Chemical and Biological Defense Program for effective therapeutics against these agents.

In 1961, the U.S. Army developed a live-attenuated vaccine (TC-83) against VEEV; in 1974, the Army developed a formalin-inactivated form (C-84). TC-83 is used under Investigational New Drug (IND) status to immunize at-risk laboratory personnel.  However, the vaccine has several limitations: approximately 23% of vaccinated people develop flu-like symptoms; an additional 18% do not respond to the vaccine and need a boost with C-84. Furthermore, current medical measures might not effectively address non-biological routes of exposure or genetic modifications. 

The ultimate goal of the program is to rapidly deliver qualified small molecule inhibitors against at least one alphavirus. The program will be administered in stages starting with small animal studies through non-human primate safety and pharmacokinetic studies and into a Phase I clinical trial.  Due to the complex and unprecedented nature of small molecule drug discovery and development against this class of viruses, the government encourages team arrangements as appropriate.

The effort is newly listed as Rapid Innovation Topic Number: CBO-ALPHA-01 under existing Defense Threat Reduction Agency (DTRA) Broad Agency Announcement HDTRA1-12-CHEM-BIO-BAA.

Tags: BAADefense Threat Reduction AgencyMosquito-Borne

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy